Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

Stock Information for Tonix Pharmaceuticals Holding Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.